Publication | Closed Access

Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial

Metastatic Breast CancerBreast OncologyAccess ProgramMedicineCancer ManagementClinical TrialsBreast CancerPharmacotherapyCancer TreatmentOncologyRadiation OncologyHealth Sciences